Meir Azualy, MsC

Meir Azulay (MSc) is the CEO of BioXL, bringing several decades of experience in biopharmaceutical process development and manufacturing. He previously worked at Merck-Serono, where he played a key role in the development and manufacturing of Rebif, a blockbuster drug for multiple sclerosis. Meir holds an MSc in Biochemistry from the Hebrew University in Jerusalem. Since 2005, he has founded and managed a Contract Development and Manufacturing Organization (CDMO) and co-founded several startups in the biopharma, food-tech, and biotech sectors. His extensive background in the industry positions him as a leader in advancing innovative biopharmaceutical solutions.